Newsfeeds - Spark Newswire

1 minute read

Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS

Today, 5:58 PM

Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data

ATRA

3 minute read

Dow Jumps 150 Points; Icosavax Shares Plunge

By Lisa Levin

Today, 5:58 PM

U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.

AGRX

5 minute read

89 Biggest Movers From Friday

By Lisa Levin

Today, 5:58 PM

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

ADN

2 minute read

Atara Biotherapeutics Announced Overall Response Rate of 60% Observed in Patients with Relapsed or Refractory EBV+ PTLD Consistent with Previously Reported Studies; Data Presented at ASCO

By Charles Gross

Today, 5:58 PM

Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced EMA regulatory progress and tabelecleucel (tab-cel®) clinical outcomes.

ATRA

1 minute read

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

By Vandana Singh

Today, 5:58 PM

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara’s mesothelin-targeted allogeneic…

ATRA

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here’s What You Need To Know

By Benzinga Insights

Today, 5:58 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.

ATRA

1 minute read

HC Wainwright & Co. Maintains Buy on Atara Biotherapeutics, Lowers Price Target to $29

By Benzinga Newsdesk

Today, 5:58 PM

HC Wainwright & Co. analyst Robert Burns maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and lowers the price target from $31 to $29.

ATRA

3 minute read

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn’s Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

By Vandana Singh

Today, 5:58 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

APRE

1 minute read

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

Today, 5:58 PM

ATHX

1 minute read

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

By Vandana Singh

Today, 5:58 PM

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG’s (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies.…

ATRA